HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.

AbstractBACKGROUND:
This post-hoc analysis examined the impact of roflumilast on chronic obstructive pulmonary disease (COPD) exacerbations and lung function in patients with COPD who received concomitant long-acting β2-agonists (LABA) with or without prior inhaled corticosteroid (ICS) and the influence of various demographic and clinical characteristics on these outcomes.
METHODS:
Data were pooled from 2 double-blind, placebo-controlled, 52-week studies of once-daily roflumilast 500 μg in patients with COPD. Endpoints were mean rate of exacerbations and change from baseline in pre- and postbronchodilator FEV1.
RESULTS:
In this pooled analysis (N = 3091), addition of roflumilast to LABAs for 1 year in patients who discontinued ICS prior to study entry (n = 945) significantly reduced the risk of COPD exacerbations vs. placebo by 19.2% (p < 0.05) and significantly improved pre- and postbronchodilator FEV1 by 40 mL and 34 mL, respectively (both, p < 0.01). Similar improvements were observed in patients who received concomitant LABAs but were not taking ICS prior to study entry (n = 597). A significant reduction in COPD exacerbation risk with roflumilast vs. placebo was observed regardless of age or smoking status, and in patients who had severe or very severe COPD. Significantly improved lung function was observed with roflumilast in all the subgroups (p < 0.05), with the exception of patients with moderate COPD.
CONCLUSIONS:
Roflumilast reduced exacerbation rates and improved lung function in patients with COPD who received concomitant LABA, regardless of prior ICS use, and across various patient subgroups regardless of age and smoking status.
CLINICALTRIALSGOV REGISTRATION NUMBERS:
NCT00297102 (M2-124) and NCT00297115 (M2-125).
AuthorsNicola A Hanania, Peter M A Calverley, Mark T Dransfield, Jill P Karpel, Manja Brose, Haiyuan Zhu, Udo-Michael Goehring, Paul Rowe
JournalRespiratory medicine (Respir Med) Vol. 108 Issue 2 Pg. 366-75 (Feb 2014) ISSN: 1532-3064 [Electronic] England
PMID24120253 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013. Published by Elsevier Ltd.
Chemical References
  • Adrenergic beta-2 Receptor Agonists
  • Aminopyridines
  • Benzamides
  • Bronchodilator Agents
  • Cyclopropanes
  • Delayed-Action Preparations
  • Phosphodiesterase 4 Inhibitors
  • Roflumilast
Topics
  • Acute Disease
  • Administration, Oral
  • Adrenergic beta-2 Receptor Agonists (administration & dosage)
  • Aminopyridines (administration & dosage)
  • Benzamides (administration & dosage)
  • Bronchodilator Agents (administration & dosage)
  • Cyclopropanes (administration & dosage)
  • Delayed-Action Preparations
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Forced Expiratory Volume (drug effects)
  • Humans
  • Male
  • Middle Aged
  • Phosphodiesterase 4 Inhibitors (administration & dosage)
  • Pulmonary Disease, Chronic Obstructive (drug therapy, physiopathology)
  • Randomized Controlled Trials as Topic
  • Smoking (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: